HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00

Nurix Therapeutics (NASDAQ:NRIX - Free Report) had its target price cut by HC Wainwright from $36.00 to $34.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Nurix Therapeutics' Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.73) EPS.

Several other brokerages also recently commented on NRIX. Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. UBS Group cut their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. Leerink Partners assumed coverage on Nurix Therapeutics in a research note on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. Wall Street Zen upgraded Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Finally, Stifel Nicolaus decreased their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.31.

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded up $0.04 on Monday, hitting $12.46. 249,554 shares of the company's stock traded hands, compared to its average volume of 846,729. The stock has a market capitalization of $952.57 million, a price-to-earnings ratio of -4.77 and a beta of 2.15. The company's fifty day simple moving average is $11.39 and its 200 day simple moving average is $13.70. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The firm had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. As a group, sell-side analysts anticipate that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares in the company, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider owned 61,516 shares of the company's stock, valued at approximately $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,013 shares of company stock valued at $137,096. Company insiders own 7.40% of the company's stock.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company lifted its stake in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after purchasing an additional 642 shares in the last quarter. Corebridge Financial Inc. raised its position in Nurix Therapeutics by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock valued at $658,000 after purchasing an additional 770 shares during the period. Kennedy Capital Management LLC lifted its position in Nurix Therapeutics by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock valued at $2,159,000 after buying an additional 785 shares during the last quarter. US Bancorp DE raised its stake in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the period. Finally, Summit Investment Advisors Inc. lifted its stake in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.